新型免疫检查点TIGIT在多发性骨髓瘤免疫治疗中的研究现状与应用前景

Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma

T细胞免疫球蛋白和免疫受体酪氨酸抑制性基序结构域(TIGIT)是近年新兴的免疫检查点蛋白,研究表明TIGIT能够使免疫细胞功能障碍,减弱抗肿瘤效应,导致肿瘤免疫耐受与免疫逃逸。通过阻断TIGIT可以逆转免疫细胞衰竭,发挥抗肿瘤效应,有望成为新一代多发性骨髓瘤治疗靶点。

T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain(TIGIT)is a new immune checkpoint protein.Studies have shown that TIGIT can cause dysfunction of immune cells,weaken the anti-tumor effect,thus leading to tumor immune tolerance and immune escape.Blocking TIGIT can reverse immune cell failure and exert anti-tumor effect,which is expected to become a new therapeutic target for multiple myeloma.